Pfizer Inc at Barclays Global Healthcare Conference Transcript
Great. Good morning. My name is Carter Gould, senior biopharma analyst here at Barclays. I am pleased to welcome Pfizer to the stage. Today, we actually -- this is a great setup because we're going to continue the immunology theme after the last talk, and we have the entire I&I squad here from Pfizer: Michael Gladstone, Global President, Inflammation & Immunology; Michael Vincent, SVP, Chief Scientific Officer, I&I; Michael Corbo, who's Chief Development Officer in I&I.
Before we get started, Bryan Dunn from the IR team is going to make a few opening comments.
Hello, everyone. Just as a reminder, the discussion with our I&I leadership team today could include forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ. If you have any questions or want more information, please see our Form 10-K or 10-Q filed with the SEC. Thanks.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
